News Roundup this Week

• FDA Approvals

  • Tislelizumab for Gastric and Gastroesophageal Junction Adenocarcinoma: The FDA has approved tislelizumab in combination with platinum and fluoropyrimidine-based chemotherapy as a first-line treatment for patients with unresectable or metastatic HER2-negative tumors.

  • Nivolumab and Hyaluronidase-nvhy for Solid Tumors: A new subcutaneous formulation combining nivolumab and hyaluronidase-nvhy has been approved, offering patients with solid tumors an alternative to intravenous PD-1 inhibitor administration.

• Telemedicine Flexibilities Extended

  • The Drug Enforcement Administration (DEA) has announced the extension of current telemedicine flexibilities for prescribing controlled medications through the end of 2025. This extension includes substances such as buprenorphine and Adderall, allowing continued access to necessary medications via telehealth services.

• Medicare Part D Changes

  • As of January 1, 2025, Medicare's new $2,000 cap on prescription drug costs has gone into full effect. This change, part of the Inflation Reduction Act, is expected to benefit approximately 19 million people, with an average saving of $400 per person

Featured Compound Formulation

Featured Video

AI application in pharmacy inventory management

 Thank you.